Skip to main content
Theralase Technologies Inc. logo

Theralase Technologies Inc. — Investor Relations & Filings

Ticker · TLT ISIN · CA88337V1004 LEI · 529900NI3Y8GLE2IBF28 TSXV Manufacturing
Open in API
Filings indexed 698 across all filing types
Latest filing 2025-05-20 Regulatory Filings
Country CA Canada
Listing TSXV TLT

About Theralase Technologies Inc.

https://theralase.com/

Theralase Technologies Inc. designs, develops, manufactures, and markets patented laser technology platforms for both bio-stimulative and bio-destructive medical applications. The company operates two core divisions. The first is Cool Laser Therapy (CLT), which utilizes proprietary super-pulsed laser systems for therapeutic purposes, focusing on pain management, inflammation reduction, tissue repair, and the effective elimination of chronic knee pain. The second is Anti-Cancer Therapy (ACT), which employs patented light-activated Photo Dynamic Compounds (PDCs) combined with laser technology for destructive applications, specifically targeting the safe and effective destruction of cancer, bacteria, and viruses.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2025-05-20 English
News release - English.pdf
Regulatory Filings
2025-05-05 English
News release - English.pdf
Regulatory Filings Classification · 75% confidence The document is a corporate news release announcing new preclinical research findings (new mechanism of action for Ruvidar™) with forward-looking statements. It is not an earnings announcement, regulatory filing like a 10-K or interim report, nor a board change, proxy, or capital transaction. It is a general press release/fallback communication, fitting the “Regulatory Filings (RNS)” category.
2025-05-01 English
Material change report - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a Canadian Form 51-102F3 Material Change Report detailing the closing of a non-brokered private placement, including the issuance of 1,995,829 units, share warrants, and gross proceeds of approximately $419,124. This is clearly a fundraising activity and a capital structure change. Therefore it best fits the Capital/Financing Update category (CAP).
2025-04-23 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings Classification · 85% confidence The document is a press release announcing a potential delay in filing the company’s annual SEC Form 20-F and application for a management cease trade order. It does not contain the annual report itself, an earnings release, management changes, or financial statements, but is a regulatory-type announcement. It falls under the fallback category of general regulatory filings (RNS).
2025-04-23 English
Notice of the meeting and record date (amended) - English.pdf
Regulatory Filings Classification · 45% confidence The document is a brief notice from TSX Trust Company confirming the record and meeting dates for the upcoming Annual General and Special Meeting of Theralase Technologies Inc. It does not contain AGM materials (presentations, slide decks, etc.) nor is it the actual proxy or information statement. It is an administrative announcement of meeting dates and record dates, which does not neatly fit any specific category like AGM-R, PSI, DVA, or DIV. Therefore it falls into the fallback category for general regulatory announcements: RNS.
2025-04-17 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.